Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
6,769 total articles
Humacyte, Inc. announced its financial results for Q4 and full year 2025 with revenues of $0.5 million and $2.0 million respectively, driven by the commercial launch of Symvess in the US and strategic international expansion efforts. The company secured a $1.475 million purchase commitment from Saudi Arabia for clinical evaluation and is pursuing r…
Radiopharm Theranostics has dosed the first patient in its Phase 1 clinical trial of RAD 402, a monoclonal antibody radiolabeled with Terbium-161, targeting KLK3 for advanced prostate cancer. The trial aims to assess safety, tolerability, biodistribution, and preliminary efficacy, with data from initial dose levels expected by mid-2026. Preclinical…
Broad Arrow Auctions, a part of Hagerty, is presenting a rare low-mileage Ferrari Monza SP2 at the Concorso d’Eleganza Villa d’Este auction in May 2026. The Monza SP2 is a highly collectible Icona series Ferrari, noted for its performance and exclusivity, expected to attract significant international bidder interest. This event highlights Broad Arr…
Diversified Energy Company announced that its President and CFO, Bradley Gray, has transferred 15,000 shares of the company's common stock to his family members as a gift, reducing his shareholding to approximately 0.30% of the company's issued share capital. The transaction was executed outside a trading venue and involved no consideration. The co…
Pharming Group announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending marketing authorization for Joenja® (leniolisib) to treat activated phosphoinositide 3-kinase delta syndrome (APDS) in patients 12 years and older. The final European Commission decision is ex…
Artelo Biosciences, a clinical-stage pharmaceutical company, has entered into definitive agreements for a private placement under Nasdaq rules to raise approximately $11 million by issuing 3.19 million common shares or pre-funded warrants along with warrants exercisable for up to 6.38 million shares. The financing proceeds will be used for working …
Toll Brothers, a leading US luxury home builder, announced the availability of two professionally designed model homes, the Aloma Coastal and Bayard Coastal, for quick move-in in their Seminole Isle community in Florida. These townhomes offer upscale living with scenic bayou views and resort-style amenities, representing the final opportunity to pu…
Zenas BioPharma announced the pricing of concurrent public offerings including $200 million aggregate principal amount of 2.50% convertible senior notes due 2032 and 5 million shares of common stock priced at $20.00 per share, aiming to raise approximately $287.5 million net proceeds. The funds will support the planned U.S. commercial launch of obe…
Moomoo, a global investment and trading platform and a subsidiary of the Nasdaq-listed FHL Holdings, is entering the second year of its partnership with the New York Mets. The collaboration aims to enhance the fan experience at Citi Field through suite experiences, interactive events, and community engagement throughout the 2026 MLB season. The par…
Cambridge Acquisition Corp., a U.S.-based SPAC listed on Nasdaq, announced that starting March 30, 2026, investors will be able to separately trade its Class A ordinary shares and warrants, which were previously bundled as units. The shares and warrants will trade under the tickers 'CAQ' and 'CAQUW' respectively, while unsplit units will continue u…
Oak Valley Community Bank, a subsidiary of Oak Valley Bancorp, has been named one of the 2026 Best Places to Work in the Central Valley based on employee feedback and independent evaluation. The bank also received recognition for growing its workforce by over 10% in 2025, highlighting its robust organizational culture and economic contribution to t…
Huize Holding Limited, a Nasdaq-listed insurance technology platform, announced strong unaudited financial results for the second half and full year of 2025. The company achieved record highs in both first year premiums and gross written premiums, with a 35.4% and 20.6% year-over-year increase respectively. Total revenue grew 26.7% to RMB1.58 billi…
Toll Brothers, Inc., a leading luxury home builder listed on NYSE as TOL, announced the final home available for purchase at its CrossCreek community in Cumming, Georgia. Priced at $1.372 million, the last opportunity offers a spacious five-bedroom residence in a highly sought-after location with top schools and amenities. This marks the closing ph…
Li Auto Inc. announced a put right notification for holders of its 0.25% Convertible Senior Notes due 2028, allowing holders to require the company to repurchase their notes at 100% principal plus accrued interest on May 1, 2026. The exercise period runs until April 29, 2026, and if all notes are tendered, Li Auto will repurchase approximately $862…
Terra Property Trust, Inc. disclosed the results of its exchange offers to swap existing unsecured senior notes due in 2026 for new secured senior notes due in 2029. While substantial tendering of existing notes occurred, the company did not receive sufficient consents to amend the indenture governing its 6.00% senior notes, so the proposed amendme…
Hudbay Minerals Inc. announced its annual mineral reserve and resource update, highlighting mine life extensions across its operations and a significantly improved three-year production forecast. The company affirmed its 2026 production guidance and issued new guidance for 2027 and 2028, projecting a 24%-28% increase in consolidated copper producti…
PMGC Holdings Inc.'s subsidiary NorthStrive Biosciences announced a third amendment to its license agreement with Korean biotech MOA Life Plus updating timelines and development milestones for dual myostatin inhibitor assets EL-32 and EL-22, focusing on muscle preservation during weight loss treatment. The amendment reflects aligned R&D and regulat…
BioXcel Therapeutics has submitted a supplemental New Drug Application (sNDA) with the FDA seeking approval for IGALMI in an at-home setting to treat acute agitation associated with bipolar disorders and schizophrenia. The timeline suggests potential approval as early as year-end 2026. The company is advancing commercial launch plans based on a rec…
Vera Therapeutics announced inducement compensation to Jane Wright-Mitchell, its newly appointed Chief Legal Officer, consisting of stock options and restricted stock units in accordance with Nasdaq rules. These awards are part of the company’s 2024 Inducement Plan and vest over four years to encourage retention and align interests with shareholder…
KANZHUN LIMITED, trading as BOSS Zhipin on Nasdaq (BZ) and HKEX (2076), announced it repurchased 506,252 shares worth approximately RMB23.6 million on March 26, 2026. Year-to-date, the company has spent more than RMB500 million on share repurchases, signaling strong commitment to enhancing shareholder returns.
Cue Biopharma announced a CEO transition with Lucinda Warren stepping in as interim president and CEO following Usman Azam's departure. Warren brings over 30 years of pharmaceutical and biotech experience and has been instrumental in securing key deals for the company. The firm plans to advance its lead autoimmune therapy, CUE-401, into clinical tr…
Presurance Holdings reported its financial results for Q4 and full year 2025, showing a deliberate exit from commercial lines with zero premium from that segment in Q4 and a 12.7% increase in personal lines production. The company continues to face significant adverse developments from prior commercial lines business, resulting in large net losses …
Editas Medicine announced that the U.S. Patent and Trademark Office has reaffirmed the Patent Trial and Appeal Board's prior decision recognizing the Broad Institute as the first inventor of CRISPR/Cas9 gene editing technology in human cells. This ruling secures critical intellectual property rights exclusively licensed to Editas for developing and…
ADMA Biologics issued a statement refuting allegations made by short seller Culper Research concerning competitive positioning, inventory management, and accounting practices. The company emphasized steady growth in demand and utilization of its ASCENIV immune globulin product over the past two years, inventory levels aligned with industry standard…
Instil Bio, Inc. disclosed its financial results for Q4 and full-year 2025, reporting a net loss but maintaining a strong cash position of $76.3 million expected to fund operations beyond 2027. The company discontinued clinical development of AXN-2510 via its subsidiary Axion Bio and is now focusing on strategic growth through potential acquisition…
